There has been a surge of interest in synthetic macrocycles in recent years as evidenced by their rising numbers in clinical trials and biopharma partnerships formed to develop them into new medicines.

Macrocycles are defined as molecules containing at least one ring composed of 8 or more atoms. There are several examples of macrocyclic drug molecules originating from natural products such as erythromycin, rapamycin, and epothilone. Macrocycles bring together the advantages of drug-like properties of small molecules with high selectivity profiles more typical of antibodies. Their size and complexity allow them to interact with targets over multiple spatially distributed interactions. The ring structures of macrocycles provide metabolic stability, thus enhancing physicochemical properties and oral bioavailability. AlloMek plans to explore macrocycles in rare diseases such as laminopathies and rasopathies.